Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial

CONCLUSION: This study is the first analysis of CTCs modeling for stage IV disease stratification. These results show the need to expand biomarker profiling in combination with CTCs stratification for improved biomarker-driven drug development.PMID:37935631 | DOI:10.1093/oncolo/oyad293

Source: The Oncologist - November 7, 2023 Category: Cancer & Oncology Authors: Lorenzo Gerratana Masha Kocherginsky Andrew A Davis Paolo D'Amico Carolina Reduzzi Fabio Puglisi Massimo Cristofanilli Source Type: research